News >

FDA Panel Narrowly Supports Ramucirumab/Erlotinib Combo in Frontline EGFR+ NSCLC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 26, 2020

The FDA's Oncologic Drugs Advisory Committee voted 6 to 5 in favor of intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva) as a frontline treatment for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x